Fig. 1From: Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective studyFlow chart of screened patients. NSCLC non-small cell lung cancer, TKIs tyrosine kinase inhibitors, EGFR epidermal growth factor receptor, SBRT stereotactic body radiation therapyBack to article page